FTSE 100 news / Companies and sectors / AstraZeneca / 3 October 2026
AstraZeneca (AZN): news on Saturday 3 October 2026
+6.0 strongly positive
Coverage was dominated by AstraZeneca's $2bn investment in Summit Therapeutics and a clinical collaboration with Daiichi Sankyo to test Datroway with ivonescimab, which was framed positively for its oncology pipeline. Other stories included rights to weight-loss drugs and a successful EU challenge, while a rival's oral GLP-1 trial win and a small share price dip tempered the tone.
What drove it
- Summit $2bn partnership
- Datroway combination trials
- weight-loss drug rights
The 34 stories
- +8.3 Summit Deal Could Help Futureproof AstraZeneca’s Datroway
Deal seen as helping extend Datroway's future - +8.3 AstraZeneca invests $2bn in Summit Therapeutics, deepening oncology ADC-bispecific ties
$2bn investment deepens oncology ADC-bispecific position - +7.5 Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
AstraZeneca's $2bn partnership with Summit announced - +7.5 AstraZeneca, Daiichi Sankyo Team With Summit on Triple-Negative Breast Cancer Trial
Trial collaboration in triple-negative breast cancer - +7.5 AstraZeneca PLC, Daiichi Sankyo And Summit Therapeutics Inc. Announce Clinical Collaboration To Evaluate Datroway In Combination With Ivonescimab Across Multiple Tumour Types
Clinical collaboration to test Datroway combination - +7.0 AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
Deepened Summit ties for ADC-bispecific combo testing - +7.0 AstraZeneca, Daiichi Sankyo, and Summit to Combine Datroway, Ivonescimab
Datroway and ivonescimab combination collaboration - +7.0 AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
Expands cancer push through Summit partnership - +7.0 AstraZeneca et Daiichi Sankyo s'associent à Summit pour tester une association de médicaments anticancéreux
Partnership to test cancer drug combination - +7.0 AstraZeneca, Daiichi team with Summit to pair Datroway with ivonescimab in Phase III TNBC push
Phase III TNBC push pairing Datroway with ivonescimab - +6.7 AstraZeneca and Daiichi Sankyo Team With Summit on Datroway Combination Trials
Datroway combination trials with Summit and Daiichi - +6.7 EU revokes Hansoh's Aumseqa nod after AstraZeneca challenge
AstraZeneca's challenge succeeded in EU revocation - +6.7 Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy
Combination therapy evaluation with Daiichi Sankyo - +6.7 AstraZeneca, Daiichi Sankyo partner with Summit to test Datroway-ivonescimab combinations
Partnership to test Datroway-ivonescimab combinations - +6.7 astrazeneca acquired rights to cspc experimental weight-loss drugs for billions
AstraZeneca acquired weight-loss drug rights, expanding pipeline - +6.3 Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
Summit partnership with AstraZeneca and Daiichi - +6.3 AstraZeneca and Daiichi add Datroway to Summit cancer collab
Datroway added to Summit cancer collaboration - +6.3 Lung and breast cancers are targets of AstraZeneca (AZN)'s new three-company trial collaboration.
Lung and breast cancer trial collaboration - +6.3 Summit Therapeutics to test ivonescimab with AstraZeneca-Daiichi ADC
Ivonescimab to be tested with AstraZeneca-Daiichi ADC - +6.3 Summit Therapeutics plans Phase III Datroway breast cancer trial
Planned Phase III Datroway breast cancer trial - +6.3 Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo
Trial collaboration with AstraZeneca and Daiichi Sankyo - +5.8 Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS
AZ's $2bn bet on ivonescimab highlighted - +5.8 AstraZeneca invests USD 2.00 billion and AstraZeneca stock costs EUR 141.25
$2bn investment reported alongside share price - +5.8 SMMT Stock Gets Another Catalyst: Summit, AstraZeneca, Daiichi Sankyo Expand Cancer Drug Push
Expanded cancer drug push with Summit and Daiichi - +5.0 Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
Roundup including AstraZeneca collaboration with Summit - +5.0 Sam Fazeli: AstraZeneca's $2 Billion Summit Bet Tests Whether Strategics See What Public Markets Can't
Commentary on AstraZeneca's strategic $2bn Summit bet - +5.0 Innovation roundup: Carnegie Mellon in Miami, AstraZeneca's $2B investment
Roundup featuring AstraZeneca's $2bn investment - +5.0 Details on Datroway and Ivonescimab Collaboration and Development
Details of Datroway and ivonescimab collaboration - −5.0 LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Lilly's oral GLP-1 beat AstraZeneca's therapies in trials - +5.0 AstraZeneca Trillion-Pound Valuation: Can the Pipeline Deliver It?
Valuation discussion hinging on pipeline delivery - +1.7 AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3
Shares slightly lower despite Phase 3 combination progress - +1.7 People on the Move: Maciej Szymaszek Named Head of Commercial AI Strategy at AstraZeneca
Minor senior hire in commercial AI strategy - −1.3 AstraZeneca stock after-hours at EUR 139.55: minus 0.61 percent versus prior close
Small after-hours share price dip - +0.3 AstraZeneca stock after-hours reference at EUR 140.40
Routine share price reference, little information
AstraZeneca: every day · Pharma and healthcare on 3 October 2026 · FTSE 100 overview for the day